,16 However, an ERT approach for CLN2 would require biweekly life-long administrations of TPP1 both to the retina and the brain, resulting in a significant reduction of the quality of life of patients and an increased risk of adverse reactions (infections and allergies). The gene discussed is TPP1; the disease is infection.